Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Eye cancer, intraocular melanoma
Stage/Subtype:  iris melanoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-10 of 10 for your search:
Start Over
Hypofractionated or Single Dose Image-Guided Radiation Therapy in Treating Patients with Metastatic Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 10-154, NCI-2010-02150, NCT01223248
Yttrium Y 90 Resin Microspheres in Treating Patients With Uveal Melanoma Who Have Liver Metastases
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10C.95, NCI-2012-00140, 2010-02, NCT01473004
Nivolumab and Ipilimumab in Treating Patients with Metastatic Uveal Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0919, NCI-2015-00853, NCI-2012-00665, NCT01585194
Cabozantinib-S-Malate Compared with Temozolomide or Dacarbazine in Treating Patients with Melanoma of the Eye
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A091201, NCI-2013-00821, CALGB-A091201, NCT01835145
Trametinib with or without GSK2141795 in Treating Patients with Metastatic Uveal Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9445, NCI-2013-02091, 13-144, NCT01979523
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13P.377, NCI-2014-00338, 2013-047, NCT02068586
Crizotinib following Surgery or Radiation Therapy in Treating Patients with High-Risk Uveal Melanoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-063, NCI-2014-01895, NCI-2015-00689, NCT02223819
Pembrolizumab in Treating Patients with Advanced Uveal Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: VICC MEL 1486, NCI-2015-00020, MEL1486, NCT02359851
Glembatumumab Vedotin in Treating Patients with Metastatic or Locally Recurrent Uveal Melanoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9855, NCI-2015-00159, NCT02363283
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
Status: Active
Phase: Phase I
Type: Treatment
Age: Over 18
Trial IDs: 201103308, NCI-2011-00484, 07-0652, 201103308 / 07-0652, NCT00683670
Start Over